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ABSTRACT
Introduction: The Biosimilars Forum
conducted a survey through an independent
organization from November 20, 2015 to
January 4, 2016 in order to assess current
levels of awareness, knowledge, and
perceptions of biosimilars among US specialty
physicians who already prescribe biologics. The
survey was intended to provide a baseline level
of knowledge about biosimilars and will be
repeated in 2–3 years in order to monitor trends
over time.
Methods: A 19-question survey was created by
the Biosimilars Forum and was administered by
an independent third party.
Results: Responses were obtained from 1201 US
physicians across specialties that are high
prescribers of biologics, including
dermatologists, gastroenterologists, hematologist-
oncologists, medical oncologists, nephrologists,
and rheumatologists.
Conclusions: The results of this survey
highlight a significant need for evidence-based
education about biosimilars for physicians
across specialties. Five major knowledge gaps
were identified: defining biologics, biosimilars,
and biosimilarity; understanding the approval
process and the use of ‘‘totality of evidence’’ to
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evaluate biosimilars; understanding that the
safety and immunogenicity of a biosimilar are
comparable to the originator biologic;
understanding the rationale for extrapolation
of indications; and defining interchangeability
and the related rules regarding pharmacy-level
substitution.
Funding: Biosimilars Forum.




Biosimilars are biological products that are
approved on the basis of multiple
comparability steps that demonstrate high
similarity to an already FDA-approved
originator biologic, and that have
demonstrated no clinically meaningful
differences in quality, safety, and efficacy. As
of August 2016, three biosimilars have been
approved by the FDA, of which one has already
been marketed since September 2015.
Approximately 60 other biosimilars are in
clinical development in the US [1–4].
Although biosimilars are relatively new to
the United States (US) market, they have been
safely utilized in Europe (since 2006), Australia,
Canada, Japan, and several other countries
worldwide, resulting in more than 400 million
patient-days of exposure to more than 20
biosimilars for numerous molecules, including
recombinant human growth hormone (rhGH),
erythropoietin, filgrastim, insulin, follitropin,
infliximab, and etanercept [5–7]. As more
biosimilars enter the US market over the
coming years, they are expected to expand
patient access to life-saving medications for
difficult-to-treat diseases, such as cancer,
anemia, and endocrine and autoimmune
disorders (e.g., multiple sclerosis, rheumatoid
arthritis, psoriasis, and inflammatory bowel
disease) because they will offer an alternative
to existing biologics for Medicare, Medicaid,
and the private sector [8].
Several of the leading biosimilar sponsors
created the Biosimilars Forum in 2015 to
advance biosimilars in the US with the intent
of expanding access and availability of
biological medicines to improve health care
[9]. The Biosimilars Forum provides
evidence-based information to inform and
support public policies that encourage
awareness, access, and adoption of biosimilars.
Current members include: Allergan, Amgen,
Boehringer-Ingelheim, Coherus, EMD-Serono,
Merck, Pfizer, Samsung Bioepis, Sandoz, and
Teva.
When generic drugs first became available
in the US in the 1980s, physicians required a
clear understanding of this new class of drugs
before they were comfortable prescribing
them to patients [10]. Similarly, it is
expected that physicians will also require an
in-depth understanding of biosimilars before
they feel comfortable offering these new
treatment options to their patients. In order
to assess current levels of awareness,
knowledge, and perceptions of biosimilars
among specialty physicians who already
prescribe biologics, the Biosimilars Forum
conducted a survey through an independent
organization from November 20, 2015 to
January 4, 2016. The survey was intended to
provide a baseline level of knowledge among
specialty physicians. A similar survey will be
conducted in 2–3 years time with the same
design in order to monitor trends in the
awareness, knowledge, and perceptions of
biosimilars over time.
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METHODS
A 19-question survey was created by the
Biosimilars Forum, and a third-party
organization, SERMO (a global social network
organization for physicians), was contracted to
conduct the survey. An attempt was made to
word all questions in a neutral manner.
Respondents were not informed that
pharmaceutical companies had created the
questionnaire because it was felt that
knowledge of this fact might bias the responses,
although it was prospectively planned to disclose
this fact at the time of publication. Responses
were obtained from 1201 US physicians across
specialties that are high prescribers of biologics,
including dermatologists, gastroenterologists,
hematologist-oncologists, medical oncologists,
nephrologists, and rheumatologists. The profile
of SERMO US physician members closely mirrors
that of all US physicians (as measured by the
American Medical Association (AMA)) [11]. The
anonymous respondents represented a
cross-section of years of experience primarily
between 6 and 30 years, although the largest
portion of respondents was in practice for
11–20 years (32.8%). Survey respondents who
did not prescribe biologics were excluded from
the survey, and were not counted among the
1201 participants.
The survey examined a range of topics
important to establish the foundation of
biosimilars in the US, including: physician
understanding of biosimilars and perceptions
of critical quality attributes; safety and efficacy;
biosimilarity; extrapolation; interchangeability;
approval requirements and processes; existing
and pending regulations regarding use; and
value to patients. Ongoing policy issues that
were not yet resolved by the US Food and Drug
Administration (FDA) were explicitly excluded,
although questions were posed about the
concept of interchangeability since that
concept can impact the use of biosimilar
products in the US. The survey was also
designed to gather information about
physician intent to use biosimilars in their
practice, the impact of expanded access to
biologics and biosimilars on patient costs, and
greater adherence with treatment regimens. The
survey results are limited to the specialty groups
surveyed and cannot be extrapolated to other
physician groups or healthcare professionals.
There are several limitations to the survey. At
the time of the survey, only one biosimilar was
approved and marketed in the US as a supportive
treatment for a hematology–oncology indication.
This product was first available in the US in
September 2015, only 3–4 months before the
survey was conducted. As a result, there was no
immediate need for physicians in the other
specialties surveyed to be knowledgeable about
biosimilars. The survey represents a snap shot in
time; therefore, it may not reflect the awareness,
knowledge or perceptions of biosimilars by
specialty physicians today. Biosimilars have
since received significant press coverage, and
several healthcare practitioner societies, patient
advocacy groups, companies, and trade
associations (including the Biosimilars Forum)
have initiated biosimilar educational activities
geared toward healthcare professionals after the
survey was completed.
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS AND DISCUSSION
General Awareness of Biologics
and Biosimilars
Overall, most physicians are aware of which
drugs used within their specialties are
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biologics; however, there was a sizeable
minority that did not know this information
(Fig. 1). Some physicians mistookchemical
drugs for biologics and many selected ‘‘none
of the above,’’ which indicated that they did
not recognize any of the suggested therapies as
biologics. These data reflect a lack of
understanding of what defines a biologic,
which was surprising since all physicians
included in the survey responded that they
prescribe biologic drugs. If physicians do not
know that a given drug is a biologic, it will
create an educational challenge to explain
that, after patent expiry, copies of these
therapies will be marketed as biosimilars
instead of as generic drugs.
Although the vast majority of respondents
across all specialties have heard about
biosimilars (Fig. S1 in Supplementary
Materials), their actual knowledge of the
fundamentals of biosimilars, as demonstrated
in greater detail below, was low. For example, a
sizable minority was unaware that a biosimilar
was available in the US (Fig. 2).
Most respondents (75%) appear to trust
FDA approval decisions; however, they will still
want additional information when making
treatment decisions (Fig. S2 in Supplementary
Materials). A small group of respondents
(13%), predominantly dermatologists and
rheumatologists, will not solely trust the FDA’s
assessments and decision to approve the
biosimilar and will seek more information.
Presumably, these physicians will decide which
medications to use based on their own
assessments. The survey did not probe further
into how those decisions would be made.
Understanding and Perceptions of Key
Concepts Related to Biosimilars
Only half of respondents are knowledgeable of
the concept of totality of evidence, which is a
new data evaluation paradigm used to assess a
Fig. 1 Physicians were provided with a list of drugs used
by their specialty, only some of which were biological
drugs. They were asked to identify whether each drug was a
biologic and were also given the option of selecting ‘‘None
of the above’’ or ‘‘I do not know’’. (Bars represent the mean,
with ranges provided vertically)
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biosimilar (Fig. 3) [12]. This insight is not
surprising because innovator drug
development is typically not based on
analytical data and has always included
clinical data for all indications. Physicians
have been taught to expect as such when
assessing new drugs.
One fundamental premise of biosimilars is
that a product will be clinically evaluated in one
or more indications of use, and the FDA may
‘extrapolate’ the totality of data to approve the
biosimilar for use with other indications for
which the originator biologic is approved.
While only 12% of respondents surveyed are
Fig. 2 Respondents were asked how long have biosimilars been available in the US. The correct answer is encircled
Fig. 3 Respondents were asked what criteria they believe
FDA will use to approve a biosimilar. There are three
correct responses to this question: ‘‘Data from at least one
clinical study in a patient population that is sensitive to
detect differences;’’ ‘‘A comparison of PK/PD data for the
biosimilar and its originator counterpart;’’ and ‘‘A
comparison of analytical characteristics between the
biosimilar and its originator brand counterpart’’
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comfortable with the concept of extrapolation
(Fig. S3 in Supplementary Materials), separate
questions that assessed details of extrapolation
reveal that most physicians are not familiar
with the concept. This lack of knowledge was
further highlighted at a US Advisory Committee
meeting held on July 12–13, 2016, [13] whereby
the panelists became more accepting of the
concept after it was explained that
extrapolation was based on totality of
evidence data from the originator biologic
molecule to the biosimilar molecule and not
from the clinical aspects of one indication to
another indication.
Almost 60% of respondents correctly
understood that to be approved as
‘‘interchangeable,’’ a biosimilar must be shown
to be safe and effective for back-and-forth
switching with no negative impacts to safety
or efficacy (Fig. S4a in Supplementary
Materials). However, there is a lack of
awareness or misinformation about the term
‘interchangeable’ (Fig. S4b–e). Overall,
one-third of respondents believe that the term
means that approval of a biosimilar implies
interchangeability with the originator biologic
(Fig. S4b). In fact, an additional category was
created within the US regulatory pathway for an
interchangeable product. As of the time of
writing of this article, the exact nature of the
additional information that will be needed has
not yet been defined, but is thought to include
additional clinical data beyond that provided to
establish biosimilarity. An overwhelming 80%
of the respondents were not aware that
interchangeability would enable a pharmacist
to switch between originator biologic and
biosimilar, and vice versa (Fig. S4c).
Perceptions of Safety and Efficacy
More than half of respondents are aware that
biosimilars must be comparable in safety and
efficacy to the originator biologic, although that
leaves a sizeable minority who are uncertain
about these important approval criteria (Fig. 4).
Physicians who are uncertain of this
foundational fact are more likely to have
reservations and may be cautious in adopting
biosimilars.
Nonetheless, a large percentage of
respondents are unsure or concerned about
Fig. 4 Respondents were asked which of the following statements are true when the FDA approves a biosimilar. Choices A
and B are correct
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the safety of biosimilar medicines (Fig. 5),
although the FDA can only approve a
biosimilar if the agency is convinced that the
safety profile is comparable to that of the
originator biologic. This misconception could
simply be due to a lack of knowledge, although
the higher levels of uncertainty among
rheumatologists compared to other specialties
suggests that this concern may be caused, at
least in part, by coordinated activities that raise
questions about biosimilars and the biosimilar
pathway, as biosimilars are being developed for
several leading rheumatology products
marketed in the US.
About half of respondents across all
specialties specified that they wanted to have
access to data directly evaluating the safety of
switching patient populations from the
originator biologic to its biosimilar (Fig. 6).
This highlights a potential concern of many
physicians that the very act of switching may be
dangerous because of concerns that the
biosimilars may not be structurally identical to
their reference product. It is likely that some
physicians are unaware of two factors: (1) the
primary sequence of a biosimilar must be
identical to the reference product, and (2) that
the quality attributes of all biologics (including
both originator biologics and biosimilars) often
vary from batch to batch within specified
limitations, and that this variability has not
led to safety concerns [14]. The critical quality
attributes of batches of biosimilars must also be
within the very same limits (pending FDA
issuance of a guidance on statistical
considerations for the analysis of analytic
similarity). In addition, while not specified in
the Biologics Price Competition Act of 2009
(BPCIA) [15] or in US guidance documents, as of
September 2016, all biosimilar products
approved by the FDA have incorporated at
least one switch from originator biologic to
biosimilar into their biosimilar clinical
development programs. These important
factors must be better communicated to
physicians.
Fig. 5 Respondents were asked if they believe biosimilars will be safe and appropriate for use in naı¨ve and existing patients
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More than one-third of respondents believe
that abbreviated approval translates to a greater
safety risk (Fig. 7), which may reveal a basic
misunderstanding that the ‘‘abbreviated’’
program refers to less supportive data. In fact,
the analytical data requirement is much greater
and forms the basis for the totality of evidence
supporting biosimilarity. The ‘‘abbreviated’’
portion refers only to a requirement for fewer
and smaller efficacy and safety studies because the
purpose of biosimilar clinical studies is to confirm
high similarity to the originator biologic and not
to re-establish the safety and efficacy profile that
was already established by the originator biologic.
Of the specialties, dermatologists and
rheumatologists expressed significantly higher
concerns at 43% and 48%, respectively.
Finally, the majority of physicians (85%)
appreciate that, as is true for all biologics,
the immunogenicity profile of a biosimilar
will not be completely known pre-approval
(Fig. S5 in Supplementary Materials). To
alleviate possible concerns about
immunogenicity of a given biosimilar, it will
be important to communicate the safety data
that will be obtained from post-approval
pharmacovigilance surveillance. It also may be
useful to better communicate the safety data
obtained with use of biosimilars in Europe,
where there have been more than 400 million
patient-days of experience in which no new
immunogenicity concerns have been observed
[5].
Preferred Information Sources
Peer-reviewed literature is by far the most
trusted and preferred information source for
biosimilars among physicians (82%; Fig. S6 in
Supplementary Materials). The top trusted
Fig. 6 Respondents were asked if it would be essential for doctors to have data directly evaluating the safety of switching
patients from an originator biologic to its biosimilar
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information sources include scientific journals
(88%), FDA (73%), and physician peers (64%);
however, dermatologists and rheumatologists
indicated less trust in the FDA as an information
source compared with other specialties at 64%
and 58%, respectively (Fig. S7 in Supplementary
Materials). Physician trust in media was very
low across all specialties (\5%). Journals,
physician peers, and congresses/symposia are
the primary trusted information sources for
current information on biosimilars across
specialties.
Physician Interests and Overall Thoughts
Approximately 60% of respondents are
concerned about patient compliance with
originator biologics and/or access to treatment
options (Fig. 8). A large majority of respondents
believe that biosimilars will enable increased
access and utilization, expand treatment
options, and provide savings to the US
healthcare system (Fig. S8a, b in
Supplementary Materials). Although a large
majority of respondents (91%) are open to
switching patients to a biosimilar (Fig. S9 in
Supplementary Materials), the concerns noted
above in several separate questions must be
taken into account as they may impact uptake
and utilization of biosimilars. Primarily,
physicians are open to the concept of using
biosimilars for their patients but would like to
see the supportive data for their indication.
They would also like to see switching data.
When the FDA requires one-time switch data
from originator biologic to biosimilar for
chronic conditions, the switching data will be
available but must be communicated.
Fig. 7 Respondents were asked if they believe a biosimilar will be less safe than its originator biologic because it will be
approved through an abbreviated pathway
2168 Adv Ther (2016) 33:2160–2172
Fig. 8 Respondents were asked to rate their level of agreement with the following statement: ‘‘With originator biologic
medicines, I have concerns about my patients’ compliance and/or access to treatment options’’
Fig. 9 Respondents were asked which biosimilars topics they were most interested in learning more about
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Finally, most physicians are interested in
learning more about key biosimilar concepts,
suggesting an openness to learn. Topics of
interest to physicians included product
attributes of safety and efficacy and key
concepts of biosimilars (totality of evidence,
extrapolation, interchangeability), as well as
information on access and the economics of
biosimilars (Fig. 9).
CONCLUSION
The results of this survey highlight a significant
need for evidence-based education about
biosimilars for physicians across specialties.
Although the vast majority of physicians have
heard about biosimilars, their actual knowledge
of the fundamentals of biosimilars was low, as
the portion of respondents answering correctly
rarely surpassed 50% for questions that focused
on key aspects of these therapies.
Five major knowledge gaps were identified:
defining biologics, biosimilars and
biosimilarity; understanding the approval
process and the use of ‘‘totality of evidence’’ to
evaluate biosimilars; understanding that the
safety and immunogenicity of a biosimilars are
comparable to the originator biologic;
understanding the rationale for extrapolation
of indications; and defining interchangeability
and the related rules regarding pharmacy-level
substitution. With respect to future educational
efforts, peer-reviewed literature is by far the
most trusted and preferred information source
for biosimilars among specialty physicians.
Although physicians across specialties have
generally positive attitudes toward biosimilars,
dermatologists and rheumatologists appear to be
less enthusiastic about biosimilars, particularly
due to safety concerns. These physician groups
may require more information from trusted
sources to address their current concerns.
This survey provides a baseline of of the
knowledge level of physicians about biosimilars.
A similar survey will be repeated in 2–3 years
time to monitor changes.
Biosimilar Definitions [16]
A BIOSIMILAR MEDICINE is a biologic that is
highly similar to an FDA-approved biological
medicine, known as an originator biologic. A
biosimilar must be (1) highly similar to the originator
biologic notwithstanding minor differences in
clinically inactive components, and (2) have no
clinically meaningful differences in safety or
effectiveness compared to the originator biologic
An INTERCHANGEABLE BIOLOGIC is a
biosimilar that has been demonstrated to produce the
same clinical result as its originator biologic in any
given patient. In addition, for a product that is
administered multiple times to an individual, the risk
in terms of safety or diminished efﬁcacy of alternating
between use of the interchangeable biologic and its
originator biologic is not greater than the risk of using
the originator biologic alone. Designation of
interchangeability requires additional supporting
evidence, which will be further deﬁned by the FDA
An interchangeable biologic may be substituted by a
pharmacist for the originator biologic or vice versa
without the intervention of the healthcare
professional who wrote the prescription. State laws
govern the substitution process, and communication
to the healthcare provider who wrote the prescription
may be required after the product is dispensed
EXTRAPOLATION is the process by which a
biosimilar may be approved for one or more
indications for which its reference biological product
is licensed but for which there was no head-to-head
clinical comparison. This approval is based on the
extrapolation of the totality of data obtained with the
biosimilar molecule in direct comparison to the
originator biologic. Every indication for which
extrapolation is sought must be scientiﬁcally justiﬁed
2170 Adv Ther (2016) 33:2160–2172
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